NCT03533283 2026-01-06An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaHoffmann-La RochePhase 1/2 Active not recruiting211 enrolled
NCT02500407 2025-09-12A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)Genentech, Inc.Phase 1/2 Completed713 enrolled 1 FDA